Search

Displaying results 2451 - 2460 of 10000 in total
  1. Pathway

    Bopindolol Action Pathway

    smpdb.ca/view/SMP0000657
    Drug action

    Bopindolol (also known as Sandonorm) is a selective β1 adrenergic receptor antagonist (beta blocker), which can be used for treatment of high blood pressure (hypertension) and irregular heartbeats (arrhythmias). Bopindolol also has ...

    Drugs: ATP · Potassium cation · Calcium · Bopindolol
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  2. Pathway

    Sotalol Action Pathway

    smpdb.ca/view/SMP0000660
    Drug action

    The electrophysiologic effects of sotalol may be due to its selective inhibition of the rapidly activating component of the potassium channel involved in the repolarization of cardiac cells.

    Drugs: ATP · Sotalol · Potassium cation · Calcium
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  3. Pathway

    Epinephrine Action Pathway

    smpdb.ca/view/SMP0000661
    Drug action

    Epinephrine can also be used to delay absorption of local anesthetics, constrict arterioles in skin and gut while dilating arterioles in leg muscles, increase glycogen hydrolysis to glucose in liver to … raise up blood sugar level and breaking down lipids in adipocytes.

    Drugs: ATP · Epinephrine · Potassium cation · Calcium
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  4. Pathway

    Isoprenaline Action Pathway

    smpdb.ca/view/SMP0000663
    Drug action

    Isoprenaline can bind and inhibit beta-1 adrenergic receptor on both vascular smooth muscle, which lead to inhibition of vasoconstriction in peripheral blood vessels and adrenergic stimulation of endothelial

    Drugs: ATP · Isoprenaline · Potassium cation · Calcium
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  5. Pathway

    Arbutamine Action Pathway

    smpdb.ca/view/SMP0000664
    Drug action

    Arbutamine has nonselective beta and weak alpha-1-adrenergic activity which causes increased chronotropic activity (increase in heart rate) and inotropic activity (increase myocardial contractility).

    Drugs: ATP · Arbutamine · Potassium cation · Calcium
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  6. Pathway

    Bevantolol Action Pathway

    smpdb.ca/view/SMP0000668
    Drug action

    This results in a decrease in preload and blood pressure.

    Drugs: ATP · Bevantolol · Potassium cation · Calcium
    Enzymes: Potassium voltage-gated channel subfamily E member 1, Potassium voltage-gated channel subfamily E member 2
  7. Drug

    Selegiline

    go.drugbank.com/drugs/DB01037
    ApprovedInvestigationalVet approved

    A selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. … It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability.

    Categories: Compounds used in a research, industrial, or household setting, P-glycoprotein inhibitorsSynonyms: L-Deprenalin
  8. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    Cetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … Discovered by Chevrenl in 1913, cetyl alcohol is one of the oldest known long-chain alcohol [A32209]. It may be contained in cosmetic and personal care products such as shampoos, creams and lotions.

    Synonyms: hexadecan-1-ol
  9. Drug

    Tofersen

    go.drugbank.com/drugs/DB14782
    ApprovedInvestigational

    [L46133] Continual FDA approval is contingent on clinical benefits from ongoing trials, particularly the Phase 3 ATLAST study in people with presymptomatic SOD1-ALS. … [L52735] Tofersen demonstrated efficacy in reducing the concentration of SOD1 in CSF and of neurofilament light chains in plasma over 28 weeks, although the ALS Functional Rating Scale–Revised did not

    Synonyms: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP, -(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
  10. Drug

    Ibrexafungerp

    go.drugbank.com/drugs/DB12471
    Approved

    [A235384,A235389] Similar to echinocandins, ibrexafungerp targets the fungal β-1,3-glucan synthase, which is not present in humans, limiting the chance of renal or hepatic toxicity. … [A235414,L34349] Ibrexafungerp was granted FDA approval on 1 June 2021.[L34349]

    Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesSynonyms: (1S,4AR,6AS,7R,8R,10AR,10BR,12AR,14R,15R)-15-((2R)- 2-AMINO-2,3,3-TRIMETHYLBUTOXY)-1,6A,8,10A-TETRAMETHYL-8- ((2R)-3-METHYLBUTAN-2-YL)-14-(5-(PYRIDIN-4-YL)-1H-1,2,4- TRIAZOL-1-YL)-1,6,6A,7,8,9,10,10A,10B, enfumafungin derivative B-(1,3)-D-glucan synthestis inhibitor